Genmab — December 2017
-
her på bagkant og med en passende beskeden afkølet pinot noir sidder jeg og kigger på R&D præsentationen (måske vi skal til at kalde den for "Den Unævnelige")
-
På beskrivelsen af Hexa-DR5 står der, at target er solide
-
-
har i set, at TF-ADC bliver startet op i et combo fase 2 cervical cancer - FRONT LINE i 2018
-
https://www.einpresswire.com/article/415530342/actinium-pharmaceuticals-launches-the-awe-program-aka-actinium-warhead-enabling-program-to-enable-collaborations-based-on-its-actinium-225-technology Forstår ikke at enten Genmab eller JNJ allerede har en aftale her.
-
det står ikke i ASH præsentationen. Kan at der vil blive staret fase II
-
Det blev annonceret 10/10. Fase 2 TV mono mod livmoderhalskræft. Muligt godkendelsesstudie. http://ir.genmab.com/releasedetail.cfm?ReleaseID=1043270
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind